Signify Premium Insight: Riding out the Storm: Amwell and Teladoc Financials Q4/FY2022
Published: March 2, 2023
In the face of sustained macro-economic challenges, Amwell and Teladoc continue to wage battle on several fronts. As in previous quarters, Teladoc is riding out the post-Covid storm better than its rival on several counts. But, amid the pervading global gloom, the telehealth industry is in decent overall shape; and there are some genuine bright spots in both companies’ Q4 and full-year (FY) 2022 financial results. This offers grounds for guarded optimism in 2023 and beyond.
Amwell at a Loss
By far Amwell’s most pressing challenge is how to stem losses which have been a black mark on the company’s bottom line since the end of the Covid telehealth boom. In 2022, soaring inflation intensified the problem, pushing operating expenses ever higher.